Drug Trial Radar · NCT05269966
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Last checked: Nov 20, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Mar 9, 2022
Primary completion
Aug 29, 2023
Study completion Aug 29, 2023
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated with brolucizumab. This study was conducted as part of the post-marketing regulatory commitment to the Indian Health authority.
Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
Interventions
Injection BrolucizumabBiological
Single-chain antibody fragment (scFv) Brolucizumab 6 mg was administered by Intravitreal (IVT) injection as per the Prescribing information (PI) and in line with the treating physician's clinical judgement. Patients received loading doses of brolucizumab at Day 0/Visit 1, Week 4/Visit 2 and Week 8/Visit 3. After the loading doses, at Week 16, disease activity assessment (DAA) were performed based on Best Corrected Visual Acuity (BCVA) and Optical Coherence Tomography (OCT) to assess whether the patient required q8w or q12w dosing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Characteristics of Treatment-emergent Adverse Events During the 56 Weeks of Treatment With Brolucizumab.Time frame: Adverse events were reported from first dose of study treatment until Week 48, plus 8 weeks follow up, to a maximum timeframe of 56 weeks.
- Incidence of Treatment-emergent Adverse Events During the 56 Weeks of Treatment With Brolucizumab - Ocular AEs - Preferred TermTime frame: Adverse events were reported from first dose of study treatment until Week 48, plus 8 weeks follow up, to a maximum timeframe of 56 weeks.
- Characteristics of Treatment-emergent Adverse Events During the 56 Weeks of Treatment With BrolucizumabTime frame: Adverse events were reported from first dose of study treatment until Week 48, plus 8 weeks follow up, to a maximum timeframe of 56 weeks.
- Incidence of Ocular Adverse Event (AEs) by System Organ Class (SOC) and Preferred Term (PT) During the 56 Weeks of Treatment With BrolucizumabTime frame: Adverse events were reported from first dose of study treatment until Week 48, plus 8 weeks follow up, to a maximum timeframe of 56 weeks.
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Chandigarh, India
Novartis Investigative Site
Hugli, India
Novartis Investigative Site
New Delhi, India
Novartis Investigative Site
Asarwa, Ahmedabad, India
Novartis Investigative Site
Ahmedabad, Gujarat, India
Novartis Investigative Site
Bangalore, Karnataka, India
Novartis Investigative Site
Chennai, Tamil Nadu, India
Novartis Investigative Site
Hyderabad, Telangana, India
Novartis Investigative Site
Varanasi, Uttar Pradesh, India
Novartis Investigative Site
Kolkata, West Bengal, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.